Released May 19, 2020, after the close
10-Q filed May 20, 2020, 50 days after period end · 0001493152-20-009524
Q1 2020 · 10-Q
Revenue$2.39M$2.39M −50.5% vs Q1 2019−53.7% vs Q4 2019
Net Income-$1.02M-$1.02M N/M vs Q1 2019N/M vs Q4 2019
EPS Diluted-$0.06-$0.06 N/M vs Q1 2019no prior Q4 2019 on file
Operating Income-$1,014,534N/M
Operating Cash Flow-$1,873,093N/M
Free Cash Flowderived-$1,877,550N/M
Margins · derived
Operating margin-42.4%−37.9 pt vs Q1 2019
Net margin-42.6%−36.1 pt vs Q1 2019
What the release said
The release
Same quarter
| Metric | Q1 2020 | Q1 2019 | Q1 2018 | Q1 2017 |
|---|---|---|---|---|
| Revenue | $2.39M | $4.83M | $5.76M | $5.23M |
| Net Income | -$1.02M | -$313.00K | -$409.00K | -$90.00K |
| EPS Diluted | -$0.06 | -$0.11 | -$0.16 | -$0.04 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ernexa Therapeutics Inc. · CIK 748592 · Engraved from SEC EDGAR